Wheatcroft et al. demonstrated that mice overexpressing IGFBP2 are protected against these conditions through inhibition of adipogenesis, preventing hepatic steatosis and reducing circulating leptin concentrations (40). This evidence concerns the gene IGFBP2 and fatty liver disease.